A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
Sir Michael Parkinson shares a lesser-known side effect of prostate cancer treatment
on May 22, 2019 at 2:51 am
Sir Michael Parkinson has opened up about suffering from a weak bladder, a lesser-known side effect of his treatment for prostate cancer. The 84-year-old was first given the all clear following ... […]
Pan-cancer analysis connects tumor matrisome to immune response
on May 22, 2019 at 2:23 am
Yet, little is known about the extent to which matrisome pattern is conserved in progressive tumors across diverse cancer types ... of clinical response to immune checkpoint inhibitor (ICI) treatments ... […]
She Had Stage 4 Lung Cancer, and a Mountain to Climb
on May 22, 2019 at 2:00 am
When Isabella’s lung cancer was diagnosed, in January 2018, she was not sure if she had months or even weeks to live. Bedridden and in excruciating pain with tumors in her pelvis, spine and brain, she ... […]
Harbor Branch Oceanographic Institute researches 'promising' triple-negative breast cancer treatment
on May 22, 2019 at 1:03 am
Researchers at FAU’s Harbor Branch Oceanographic Institute have been awarded a large grant to look into the chance that a chemical released by sea sponges in various oceans could treat an aggressive ... […]
Girl, 4, Celebrates End of Radiation Cancer Treatment Dressed as an Adorable Stormtrooper
on May 21, 2019 at 7:05 pm
At long last, 4-year-old Audrina Hatton-Wright was able to ring her hospital’s “cancer bell” to celebrate the end of one of her treatments to fight off a rare and deadly disease — and she ... […]
Merck buys Peloton Therapeutics to expand its kidney cancer treatment portfolio
on May 21, 2019 at 3:58 pm
Consumers in China are taking to social media to express their support for Huawei as the U.S. government looks to ramp up pressure on the Chinese smartphone maker. Shares of Saudi shopping mall ... […]
After cancer treatment, WSVN’s Phil Ferro has a forecast. ‘I’m returning to work!’
on May 21, 2019 at 8:18 am
A familiar voice weather will be returning to the airwaves after a three-month absence. Phil Ferro, WSVN-Channel 7’s chief meteorologist, was diagnosed with throat cancer in January. He has been with ... […]
Merck buys Peloton to expand its kidney cancer treatment portfolio
on May 21, 2019 at 7:41 am
(Reuters) - U.S. drugmaker Merck & Co Inc on Tuesday agreed to buy Peloton Therapeutics Inc for $1.05 billion in cash, gaining access to the privately held company’s lead kidney cancer drug candidate. ... […]
Cancer: Using 3D to test personalized treatments in five days
on May 21, 2019 at 7:39 am
Researchers have devised a cell co-culture platform that reproduces a patient's tumor structure in 3D. The scientists can use it to test several drugs or their combinations at different stages of the ... […]
via Bing News